Notizie

PECHINO, 18 maggio 2021 - Lepu Medical Technology (Pechino) Co., Ltd. ("Lepu Medical"), una società leader a livello mondiale specializzata nello sviluppo, produzione e commercializzazione di dispositivi e attrezzature mediche ad alta tecnologia, Il 14 maggio ha ospitato un "Seminario sui metodi COVID-19 per il rilevamento" virtuale per condividere la teoria e le migliori pratiche per promuovere ulteriormente il controllo e la prevenzione delle COVID-19 globali in Cina e in tutto il mondo.

Il seminar, which included a virtual training session and a virtual visit to Lepu Medical’s headquarters in Beijing, was part of the seven-day “Seminar on COVID-19 Methods For Detection,” sponsored by China’s Ministry of Commerce and organized by Beijing Holley-Cotect Pharmaceuticals Co., Ltd. Il seminar aimed to help other countries and regions to control the pandemic by sharing China’s advanced prevention and control experience. 

Tenuto virtualmente tramite video in live streaming, il seminario includeva sessioni di domande e risposte, condivisione di seminari, visite al cloud e altri formati virtuali. Un totale di 77 partecipanti, tra cui operatori sanitari, personale governativo e ricercatori in istituti di ricerca scientifica di nove paesi, tra cui Kenya, Mauritius, Venezuela, Perù, Ucraina, Sri Lanka, Iraq, Etiopia e Iran, si sono uniti alla conferenza e alla visita del cloud ospitata da Lepu Medical.

During the seminar, Lepu Medical invited Dr. Jing Yu from the Wuhan Hospital of Traditional Chinese and Western Medicine to deliver a training lecture on basic knowledge and practical experiences of SARS-COV-2 detection, antigen rapid tests, and biochemical indicators for diagnosis. Il training course covered the closed loop and seamless SARS-COV-2 detection process from sampling, sample transfer, sample receipt, testing, result reporting and medical waste treatment in various settings including medical institutions, communities, mass screening sites and public places. Il seminar, which was well-received by attendees, included a question and answer session in which Dr. Jing Yu and representatives from Lepu Medical answered detailed questions on COVID-19 detection methods, and provided best practice advice to attendees. 

Lepu Medical’s Kit rapido della prova dell'antigene 2019-nCoV (immunocromatografia colloidale dell'oro), a simple screening method for COVID-19 that delivers quick results with high negative predictive value (NPV), was held up as an example by Dr. Yu during the training session. Il antigen test method, which is non-invasive, simple to use, cost-efficient, convenient, rapid, stable and accurate has shown high sensitivity of 95.06% and high specificity of 99.62% in clinical trials in IPE Center for Clinical Laboratory, a Lepu Medical subsidiary. Results can be quickly retrieved in 15 minutes. Lepu Medical provides both Lepu Professional Antigen test kits for use by medical institutions and Lepu Antigen self-test kits for individual self-test use, to support diverse testing needs. Il Lepu Antigen self-test kit is already approved by BfArM and available in Germany. 

“(For the antigen rapid test,) the positive results can be seen in the early stage after the symptoms (emerged) or in the infection,” said Dr. Yu, addressing participant questions raised about test timing and sensitivity during the lively Q&A session following her lecture, “Il sensitivity of the antigen detection depends on the prevalence of the virus. Il positive rate of the antigen rapid test is useful in the high prevalent area. If the viral load of the sample is high, the sensitivity of the antigen test and PCR test can be the same.  All biomarkers combined together can be the most effective.”

In addition to the Kit rapido della prova dell'antigene 2019-nCoV (immunocromatografia colloidale dell'oro), Lepu Medical offers other comprehensive diagnostic solutions including nucleic acid series products and solutions, which provide standard tests for COVID-19 diagnosis, and neutralization antibody test products to detect the effectiveness of COVID-19 vaccines in the post-pandemic period. Other COVID-19 products and solutions include sample collection kits, manual sample extraction kits, automated sample extractors, nucleic acid test kits, real-time PCR systems for standard clinical nucleic acid diagnostics, and antibody test kits and systems for vaccine effect evaluation.

Lepu Medical has been providing proactive support to control the COVID-19 pandemic from an early stage. In early 2020, during the outbreak in China, Lepu Medical started emergency production of medical equipment supplies and donated more than RMB5 million of personal protective equipment (PPE), medical devices and cash to severely impacted areas. Il company also developed an online free medical consulting system “Doctor Lepu” to assist patients remotely while supporting social distancing. Lepu Medical subsidiaries also dispatched volunteers and a medical aid team to the city of Wuhan and provided mass COVID-19 nucleic acid testing in Beijing where the company is headquartered. Lepu Medical’s products were also widely used across China’s hospitals, medical centers and COVID-19 testing sites. Ilse products included Lepu Medical’s automatic PCR analysis system, personal forehead thermometers, pulse oximeters, monitors, electrocardiographs, household oxygen generators and pharmaceutical products.

In qualità di azienda globale che copre più di 80 paesi e regioni con oltre 20 partner OEM globali, Lepu Medical ha sfruttato la sua rete globale e le sue risorse in ricerca e sviluppo, produzione e distribuzione per supportare gli sforzi mondiali per contrastare COVID-19. Vari prodotti rilevanti dell'azienda hanno ottenuto il certificato CE in Europa e sono stati approvati dalla Food and Drug Administration (FDA) statunitense e distribuiti in oltre 140 paesi per combattere la pandemia. Lepu Medical ha sostenuto test di massa regolari in più paesi, assistendo nella riapertura organizzata delle scuole in Austria fornendo oltre 20 milioni di kit di test dell'antigene per condurre test a livello nazionale a partire da gennaio 2021. Il kit di test rapido dell'antigene SARS-CoV-2 Lepu, elencato nella whitelist cinese per l'esportazione, è certificato dall'istituto ufficiale PEI in Germania e ha ottenuto un'approvazione speciale dall'Istituto federale tedesco per i farmaci e i dispositivi medici (BfArM) per l'autotest.

Upholding the company’s spirit of integrity, quality and scientific innovation, Lepu Medical will continue to focus on combating the COVID-19 pandemic and go above and beyond to provide the best quality of products and services to satisfy the needs of healthcare professionals and patients.